Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 1.00 |
| ▸ | GRM5 | P41594 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079820 | 1.00 | CYP1A2 (1.00) | CYP1A2GRM5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL29970882 | 1.00 | CYP1A2 (1.00) | CYP1A2GRM5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL12498342 | 0.90 | CYP1A2 (1.00) | CYP1A2GRM5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15890655 | 0.90 | GRM5 (0.82) | CYP1A2GRM5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15890689 | 0.89 | CYP3A4 (1.00) | CYP1A2GRM5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15890681 | 0.89 | CYP1A2 (0.79) | CYP1A2GRM5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15890739 | 0.88 | CYP1A2 (1.00) | CYP1A2GRM5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15890680 | 0.87 | GRM5 (0.77) | CYP1A2GRM5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15890702 | 0.86 | CYP1A2 (0.76) | CYP1A2GRM5CYP2C9KCNH2CYP3A4 | |
| SCHEMBL15890732 | 0.86 | CYP1A2 (1.00) | CYP1A2GRM5CYP2C9KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098030-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | UNIV VANDERBILT (US) | 2026-04-09 | — | — | US | disclosed |
| US-20240208983-A1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | VANDERBILT UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| US-20240199640-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | VANDERBILT UNIVERSITY | 2024-06-20 | — | — | US | disclosed |
| US-20240199641-A1 | QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | UNIV VANDERBILT (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2023279193-A9 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-04-27 | — | — | WO | disclosed |
| US-10538491-B2 | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators | VANDERBILT UNIVERSITY (US) | 2020-01-21 | — | — | US | disclosed |
| US-10399948-B2 | Negative allosteric modulators of metabotropic glutamate receptor 3 | VANDERBILT UNIVERSITY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180072674-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | VANDERBILT UNIVERSITY (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180022712-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-9676782-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of metabotropic glutamate receptor 3 | VANDERBILT UNIVERSITY (US) | 2017-06-13 | — | — | US | disclosed |
| WO-2016130652-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | VANDERBILT UNIVERSITY (US) | 2016-08-18 | — | — | WO | disclosed |
| US-20160214940-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | VANDERBILT UNIVERSITY | 2016-07-28 | — | — | US | disclosed |
| US-9382208-B1 | Negative allosteric modulators of metabotropic glutamate receptor 2 | VANDERBILT UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | VANDERBILT UNIVERSITY | 2015-12-17 | — | — | US | disclosed |
| US-9085562-B2 | 6-alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085562-B2 | 6-alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140206707-A1 | 6-ALKYL-N-(PYRIDIN-2-YL)-4-ARYLOXYPICOLINAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206707-A1 | 6-ALKYL-N-(PYRIDIN-2-YL)-4-ARYLOXYPICOLINAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2680849-A2 | 6-ALKYL-N-(PYRIDIN-2-YL)-4-ARYLOXYPICOLINAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | Vanderbilt University (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012118563-A2 | 6-ALKYL-N-(PYRIDIN-2-YL)-4-ARYLOXYPICOLINAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10538491-B2 | 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators | GRM2, GRIA2, GRIN2A | CYP1A2 1014/4885GRM5 5/4885CYP2C9 1489/4885 |
| US-20140206707-A1 | 6-ALKYL-N-(PYRIDIN-2-YL)-4-ARYLOXYPICOLINAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | CYP1A2 3163/4885GRM5 1/4885CYP2C9 3619/4885 |
| US-20240199640-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM2, GRIN2A, GRIN2C | CYP1A2 2576/4885GRM5 11/4885CYP2C9 3574/4885 |
| US-20240199641-A1 | QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM2, GRIN2A, GRIN2C | CYP1A2 1890/4885GRM5 12/4885CYP2C9 2948/4885 |
| US-20260098030-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM2, GRM1, GRIN2C | CYP1A2 2194/4885GRM5 21/4885CYP2C9 3229/4885 |
| US-20180022712-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | GRM3, GRM1, GRIN3A | CYP1A2 4630/4885GRM5 8/4885CYP2C9 4369/4885 |
| US-10399948-B2 | Negative allosteric modulators of metabotropic glutamate receptor 3 | GRM3, GRM1, GRIN3A | CYP1A2 4630/4885GRM5 8/4885CYP2C9 4369/4885 |
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | GRM3, GRM1, GRIN3A | CYP1A2 4630/4885GRM5 8/4885CYP2C9 4369/4885 |
| US-20240208983-A1 | 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM2, GRM1, GRM3 | CYP1A2 1995/4885GRM5 11/4885CYP2C9 2782/4885 |
| US-20160214940-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM2, GRM1, GRIN2A | CYP1A2 3561/4885GRM5 6/4885CYP2C9 4042/4885 |
| US-20180072674-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM2, GRM1, GRIN2A | CYP1A2 3561/4885GRM5 6/4885CYP2C9 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.